Isis Pharmaceuticals (www.isispharm.com) has developed an antisense drug candidate that continues to show potential in treating patients with cardiovascular diseases by reducing cholesterol, LDL-C, as ...
Isis will be responsible for global development of ISIS-SMN Rx through the completion of Phase 2/3 registrational clinical trials, with Biogen Idec providing advice on the clinical trial design and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results